Market Place
Sourcing Support
Fortress Biotech Reports Q1 2025 Financial Results and Highlights
15 May 2025 //
GLOBENEWSWIRE
Sentynl`s CUTX-101 NDA Gets FDA Priority Review For Menkes Disease
06 Jan 2025 //
PR NEWSWIRE
Fortress Biotech Pauses Dividends On 9.375% Series A Preferred Stock
05 Jul 2024 //
GLOBENEWSWIRE
Fortress Doses First Patient In Triplex Liver Transplant CMV Study
14 May 2024 //
GLOBENEWSWIRE
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS
04 Mar 2024 //
GLOBENEWSWIRE
Cyprium Therapeutics Completes Asset Transfer of CUTX-101 Product Candidate
06 Dec 2023 //
GLOBENEWSWIRE
Fortress Subsidiary Helocyte Announces Option Agreement with City of Hope
16 Oct 2023 //
GLOBENEWSWIRE
Fortress to Present at H.C. Wainwright 25th Annual Global Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
03 Aug 2023 //
GLOBENEWSWIRE
Urica Announces Topline Data from the Ph1 Trial Evaluating Dotinurad
29 Jun 2023 //
GLOBENEWSWIRE
Aevitas Therapeutics Announces Asset Purchase Agreement with 4D Molecular
24 Apr 2023 //
GLOBENEWSWIRE
Helocyte Announces Data from Stem Cell Transplant Donor Vaccination Trial
16 Feb 2023 //
GLOBENEWSWIRE
Fortress Announces Closing of $13.9M Registered Offering Priced At-the-Market
10 Feb 2023 //
GLOBENEWSWIRE
Fortress Announces Pricing of $13.9M Registered Direct Offering
08 Feb 2023 //
GLOBENEWSWIRE
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
19 Dec 2022 //
GLOBENEWSWIRE
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin
14 Dec 2022 //
GLOBENEWSWIRE
Fortress Biotech Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Lindsay Rosenwald’s Fortress Bio Positioned for Biotech Winter
31 Oct 2022 //
FIERCEBIOTECH
Fortress Biotech Announces Timing of Regular Monthly Dividend for October
05 Oct 2022 //
GLOBENEWSWIRE
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide $20 M
11 Aug 2022 //
GLOBENEWSWIRE
Fortress Biotech Reports Q2 2022 Rusult and Recent Corporate Highlights
11 Aug 2022 //
GLOBENEWSWIRE
Fortress Biotech Appoints David Jin as Chief Financial Officer
22 Jul 2022 //
GLOBENEWSWIRE
Fortress Biotech Announces First Patient Dosed in PI Trial of Dotinurad
31 May 2022 //
GLOBENEWSWIRE
Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
18 May 2022 //
GLOBENEWSWIRE
Fortress Biotech Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Fortress Biotech to Present at 21st Needham Virtual Healthcare Conference
07 Apr 2022 //
GLOBENEWSWIRE
Fortress Biotech Announces Virtual Two-Day R&D Summit
01 Apr 2022 //
GLOBENEWSWIRE
Fortress Biotech Reports Record 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Fortress Biotech, Cyprium Tx, Sentynl Tx Announce CUTX-101 Data at 2022 ACMG
21 Mar 2022 //
GLOBENEWSWIRE
Fortress Biotech to Participate in Three March 2022 Investor Conferences
09 Mar 2022 //
GLOBENEWSWIRE
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit
03 Mar 2022 //
GLOBENEWSWIRE
Fortress Biotech to Participate in 2nd Annual Winter Wonderland Conference
07 Feb 2022 //
GLOBENEWSWIRE
Fortress Biotech to Participate in H.C. Wainwright BioConnect Virtual Conference
06 Jan 2022 //
GLOBENEWSWIRE
Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex
16 Dec 2021 //
GLOBENEWSWIRE
Fortress, Cyprium &Sentynl Announce the Initiation of Rolling sNDA for CUTX-101
07 Dec 2021 //
GLOBENEWSWIRE
Fortress shares jump 14%; analysis of data from CUTX-101 Menkes trials
08 Oct 2021 //
SEEKINGALPHA
Fortress Biotech and Cyprium Announce Positive Clinical Data for CUTX-101
08 Oct 2021 //
GLOBENEWSWIRE
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AZ
06 Oct 2021 //
GLOBENEWSWIRE
Fortress Biotech Announces Receipt of Notice of Option Exercise from AZ
29 Sep 2021 //
GLOBENEWSWIRE
Fortress Biotech Reports Record Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
A snakebit biotech receives second CRL for reformulated pain med
14 Jun 2021 //
ENDPTS
Mustang Bio to Host KOL Webinar on MB-106 CD20-Targeted CAR T
07 Jun 2021 //
GLOBENEWSWIRE
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin
10 May 2021 //
GLOBENEWSWIRE
Fortress Biotech’s Partner Company, Journey Medical Corporation
22 Mar 2021 //
GLOBENEWSWIRE
Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl
24 Feb 2021 //
GLOBENEWSWIRE
Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101
15 Dec 2020 //
GLOBENEWSWIRE
Fortress Biotech Announces Oral and Poster Data Presentations
04 Nov 2020 //
GLOBENEWSWIRE
Fortress Biotech Announces Initiation of Studies of CAEL-101 in AL Amyloidosis
14 Sep 2020 //
GLOBENEWS WIRE
Fortress Biotech takes out $60M loan for debt purposes
28 Aug 2020 //
ENDPTS
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
26 Aug 2020 //
GLOBENEWSWIRE
Fortress Biotech Announces Positive Opinion on Orphan Drug Designation
31 Jul 2020 //
GLOBENEWSWIRE
Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence
11 Jun 2020 //
GLOBENEWSWIRE
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
26 May 2020 //
GLOBENEWSWIRE
Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101
16 Jan 2020 //
GLOBE NEWSWIRE
Fortress Joins hands with AstraZeneca to fight CNS Disorders in Children
24 Dec 2019 //
PIPELINE REVIEW
